Open an account

Vyne Therapeutics

YARW · NASDAQ

$20.21+$0.23 (+1.15%)TodayMarket closed ·
Prev close $19.98

About YARW

VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. The company is headquartered in Bridgewater, New Jersey and currently employs 10 full-time employees. The company went IPO on 2018-01-25. The company is developing VYN202, an oral, small molecule BD2-selective BET inhibitor. VYN202 is an oral, small molecule BD2-selective BET inhibitor that has been designed to achieve potential class-leading potency and selectivity for BD2 vs. BD1. The firm has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating.

Employees
10
Headquarters
Bridgewater, New Jersey
Listed
Jan 25, 2018
Sector
Health Care
Industry
Pharmaceuticals
Website
vynetherapeutics.com

YARW key statistics

Market cap
1.09B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
131.61K
Volume
105.89K
Open price
$19.87
High today
$20.49
Low today
$19.33
52 Week high
$46.95
52 Week low
$16.04

Vyne Therapeutics (YARW) at a glance

Vyne Therapeutics (YARW) last traded at $20.21, with a market cap of 1.09B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $19.33 and $20.49. The current price is 4.6% above the day's low and 1.4% below its high.

Volume so far is 105.89K shares, in line with the average of 131.61K shares a day.

Over the past year Vyne Therapeutics has ranged from $16.04 to $46.95, and now sits 13% of the way up that range.

Vyne Therapeutics met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q1 FY26 it reported -$4.00 per share against an estimate of -$9.18.

The average analyst price target is $72.76, 260.0% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 2 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 5 analystsAvg $72.76
Low
$56.56
Now
$20.21
High
$105.00

YARW earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 35.9% on average.

  1. Q2 FY24: reported -$0.22 per share against an estimate of -$0.1938
  2. Q3 FY24: reported -$0.29 per share against an estimate of -$0.2397
  3. Q4 FY24: reported -$0.28 per share against an estimate of -$0.3094
  4. Q1 FY25: reported -$0.20 per share against an estimate of -$0.2958
  5. Q2 FY25: reported -$0.13 per share against an estimate of -$0.2278
  6. Q3 FY25: reported -$0.17 per share against an estimate of -$0.1326
  7. Q4 FY25: reported -$5.65 per share against an estimate of -$9.18
  8. Q1 FY26: reported -$4.00 per share against an estimate of -$9.18

YARW news

  • Press releaseBusiness Wire

    Yarrow Bioscience Announces Closing of its $172.5 Million Underwritten Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

  • Press releaseBusiness Wire

    Yarrow Bioscience Announces Pricing of $150 Million Underwritten Public Offering

  • Press releaseBusiness Wire

    Yarrow Bioscience Announces Proposed Underwritten Public Offering

  • Press releaseBusiness Wire

    Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update

  • Press releaseBusiness Wire

    Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves’ Disease and Thyroid Eye Disease

Similar companies

Companies in the same industry as Vyne Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.